Clinical Trials at Duke Comprehensive Cancer Center

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact Renee Welch, RN or Karen Atwater, RN at (919) 660-1278.

Trial Phase Breast Cancer
00007235 II Adjuvant paclitaxel and trastuzumab for node-negative HER2-positive breast cancer
00015169 III A Randomized, Multicenter, Phase III Open-Label Study Of The Efficacy And Safety Of Trastuzumab-Mcc-Dm1 Vs. Capecitabine + Lapatinib In Patients With Her2-Positive Locally Advanced Or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based
00009899 III CALGB 60202 A Correlate to CALGB 40101
00009899 III CALGB 40101: Cyclophosphamide and Doxorubicin (CA x 4 cycles) versus Paclitaxel (4 cycles) as Adjuvant Therapy for Women with Node-Negative Breast Cancer: A 2x2 Factorial Phase III Randomized Study.
00014267 N/A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy with Doxorubicin (A)/ Cyclophosphamide (C) and/or Weekly Paclitaxel (P).
00006996 III A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25mg daily), Letrozole (2.5mg), or Anastrozole (1mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer
00014340 I A Phase I, Dose Escalation and Pharmacokinetics Study of Temperature Sensitive Liposome Encapsulated-Doxorubicin (ThermoDox) and Hyperthermia in Patients with Local-Regionally Recurrent Breast Cancer
00014271 I A Phase Ib Study With Biologic Endpoints Of Paclitaxel and 2-Methoxyestradiol (Panzem Nanocrystal Colloidal Dispersion) In Metastatic Breast Cancer
00014988 I/II A Phase I/II Clinical Trial Assessing the Safety and Efficacy of BZL 101 for Metastatic Breast Cancer
9260 III A Phase III, Multicenter, Randomized, Placebo-Controlled Trial Evaluating The Efficacy And Safety Of Bevacizumab In Combination With Chemotherapy Regimens In Subjects With Previously Treated Metastatic Breast Cancer
00014837 II A Phase II Study of Abraxane, Carboplatin and Bevacizumab in Triple Negative (Demonstrating no Expression for Estrogen, Progesterone, or HER2 Receptors) Metastatic Breast Cancer
5518 I Phase I, Open-Label Study of the Safety, Pharmacokinetics and Pharmacodynamics of GW572016 in Once Daily Vs. Twice Daily Dosing Regimens in Patients with Treatment-Naive Breast Cancer
00010021 II Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients with Relapsed or Refractory Inflammatory Breast Cancer.
00014926 II A Phase II Safety and Tolerability Study of Bevacizumab when Added to Single Agent Chemotherapy to Treat Patients with Breast Cancer Metastatic to the Brain
00002106 II A Phase II Efficacy and Tolerability Study of RTA744 in Breast Cancer Patients with Progression of Previously Irradiated Brain Metastasis
Duke Comprehensive Cancer Center Accolades